Levodopa-related cysteinyl–glycine and cysteine reduction with and without catechol-O-methyltransferase inhibition in Parkinson’s disease patients

被引:0
作者
Thomas Müller
Siegfried Muhlack
机构
[1] St. Joseph Hospital Berlin-Weissensee,Department of Neurology
[2] Ruhr University Bochum,Department of Neurology, St. Josef Hospital
来源
Journal of Neural Transmission | 2014年 / 121卷
关键词
Cysteinyl–glycine; Cysteine; Oxidative stress; Parkinson’s disease;
D O I
暂无
中图分类号
学科分类号
摘要
Oxidative stress is influenced by the thiol homeostasis, which regulates the redox milieu via glutathione. Components of glutathione metabolism are cysteine and cysteinyl–glycine. Both substrates decay following levodopa application or dopamine-related oxidative stress. Objective was to investigate the impact of an acute levodopa application with and without catechol-O-methyltransferase inhibitor on cysteine- and cysteinyl–glycine plasma levels. On two investigation days, 13 patients with Parkinson’s disease took one retarded release 200-mg levodopa/50 mg carbidopa-containing tablet or one 150-mg levodopa/50-mg carbidopa/200-mg entacapone formulation under standardized conditions. Levodopa, 3-O-methyldopa, cysteine and cysteinyl–glycine were measured at baseline, 80 and 140 min following levodopa administration. Cysteine and cysteinyl–glycine similarly decreased, levodopa was nearly equal during both conditions. Entacapone lowered 3-O-methyldopa. Cysteine decay may be due to an elevated glutathione generation, which consumes cysteine. Cysteinyl–glycine decrease results from the alternative glutathione transformation to its oxidized form glutathione dissulfide after free radical scavenging.
引用
收藏
页码:643 / 648
页数:5
相关论文
共 131 条
  • [1] Allen GF(2013)Dopamine but not Neurochem Int 62 684-694
  • [2] Ullah Y(2004)-dopa stimulates neural glutathione metabolism. Potential implications for Parkinson’s and other dopamine deficiency states N Engl J Med 351 2498-2508
  • [3] Hargreaves IP(2006)Levodopa and the progression of Parkinson’s disease Naunyn Schmiedebergs Arch Pharmacol 372 257-266
  • [4] Land JM(2009)Pramipexole protects against H2O2-induced PC12 cell death Neurochem Int 55 760-767
  • [5] Heales SJ(2013)Neuroprotective effect of the antiparkinsonian drug pramipexole against nigrostriatal dopaminergic degeneration in rotenone-treated mice PLoS ONE 8 e66639-2648
  • [6] Fahn S(2003)Neuropathy in Parkinson’s disease patients with intestinal levodopa infusion versus oral drugs Life Sci 72 2641-66
  • [7] Oakes D(1997)A pharmacological analysis elucidating why, in contrast to (−)-deprenyl (selegiline), alpha-tocopherol was ineffective in the DATATOP study Clin Neuropharmacol 20 55-855
  • [8] Shoulson I(2011)Effect of Expert Opin Drug Metab Toxicol 7 847-718
  • [9] Kieburtz K(2013)-dopa and the catechol- Expert Rev Neurother 13 707-932
  • [10] Rudolph A(2009)-methyltransferase inhibitor Ro 41-0960 on sulfur amino acid metabolites in rats Mov Disord 24 929-546